ML-007C-MA for Alzheimer's Disease Psychosis
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug ML-007C-MA for treating psychosis in Alzheimer's disease?
The research highlights that new drug approaches, like pimavanserin, show promise for treating psychosis in dementia, and existing drugs such as escitalopram and vitamin D might be useful but need more exploration. This suggests that similar treatments to ML-007C-MA could potentially be effective for Alzheimer's-related psychosis.12345
What makes the drug ML-007C-MA unique for treating Alzheimer's disease psychosis?
The research does not provide specific information about ML-007C-MA, but it highlights the need for new treatments for Alzheimer's disease psychosis, as current options are limited and often lack safety and effectiveness. Novel approaches, like pimavanserin, are being explored, suggesting that ML-007C-MA might offer a new mechanism or improved safety profile.13678
What is the purpose of this trial?
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
Research Team
MapLight Therapeutics
Principal Investigator
MapLight Therapeutics
Eligibility Criteria
This trial is for men and women aged 55 to 90 with Alzheimer's Disease who are experiencing hallucinations and delusions. Participants must be diagnosed with Alzheimer's-related psychosis but the full eligibility criteria are not provided.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ML-007C-MA or placebo for the treatment of hallucinations and delusions associated with Alzheimer's Disease Psychosis
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ML-007C-MA
Find a Clinic Near You
Who Is Running the Clinical Trial?
MapLight Therapeutics
Lead Sponsor